bioAffinity Technologies Inc. has announced the issuance of a U.S. patent for their innovative cancer therapy, which utilizes small interfering RNAs (siRNAs) to target and silence specific cell surface receptors, CD320 and LRP2. This approach has shown promise in selectively killing cancer cells across various types, including lung, breast, prostate, brain, and skin cancers, while sparing normal cells. The company also received notification of a patent grant from the China National Intellectual Property Administration, signaling potential global impact for their therapeutic advancements.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。